Why ß-blockers are not cardioprotective in elderly patients with hypertension

Current Cardiology Reports

Volumn 4, Issue 6, 2002, Pages 468-473

  Grossman, Ehud ^a   Messerli, Franz H ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; COMORBIDITY; DRUG EFFECT; HEART; HEART OUTPUT; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; REVIEW; VASCULAR RESISTANCE;

ADRENERGIC BETA-ANTAGONISTS; AGED; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIOVASCULAR SYSTEM; COMORBIDITY; HEART; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; VASCULAR RESISTANCE;

EID: 0036830861     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0108-3     Document Type: Article

References (71)

1. Arch Intern Med 1998, 158:573.
2. Arch Intern Med 1997, 157:2413-2446.
3. Messerli FH, Grossman E, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998, 279:1903-1907.
4. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992, 304:405-412.
5. Lever AF, Brennan PJ: MRC trial of treatment in elderly hypertensives. Clin Exp Hypertens 1993, 15:941-952.
6. Dahlof B, Devereux RB, Kjeldsen SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
7. Hoes AW, Grobbee DE, Lubsen J, et al.: Diuretics, betablockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995, 123:481-487.
8. Dahlof B, Lindholm LH, Hansson L, et al.: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338:1281-1285.
9. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264.
10. Kostis JB, Berge KG, Davis BR, et al.: Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am J Hypertens 1995, 8:1147-1153.
11. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ (Clin Res Ed) 1986, 293:1145-1151.
12. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. BMJ (Clin Res Ed) 1985, 291:97-104.
13. The IPPPSH Collaborative Group: Cardiovascular risk and risk factors in a randomized trial of treatment based on the betablocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985, 3:379-392.
14. Wilhelmsen L, Berglund G, Elmfeldt D, et al.: Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987, 5:561-572.
15. Staessen J, Fagard R, Amery A: Primary prevention with metoprolol in patients with hypertension [letter]. JAMA 1988, 260:1713-1714.
16. Materson BJ, Reda DJ, Cushman WC, et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993, 328:914-921.
17. Philipp T, Anlauf M, Distler A, et al.: Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ 1997, 315:154-159.
18. Dickerson JE, Hingorani AD, Ashby MJ, et al.: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353:2008-2013.
19. Di Iorio A, Marini E, Lupinetti M, et al.: Blood pressure rhythm and prevalence of vascular events in hypertensive subjects. Age Ageing 1999, 28:23-28.
20. Zweiker R, Eber B, Schumacher M, et al.: "Non-dipping" related to cardiovascular events in essential hypertensive patients. Acta Med Austriaca 1994, 21:86-89.
21. Bianchi S, Bigazzi R, Baldari G, et al.: Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994, 7:23-29.
22. Voogel AJ, van der Meulen JH, van Montfrans GA: Effects of antihypertensive drugs on the circadian blood pressure profile. J Cardiovasc Pharmacol 1996, 28:463-469.
23. Azuma T, Matsubara T, Nagai Y, et al.: Effects of antihypertensive agents on circadian blood pressure in hypertensive patients with previous brain infarction. J Hum Hypertens 1997, 11:637-640.
24. Cleophas TJ, van der Meulen J, van de Luit L, Zwinderman AH: Daytime-selective antihypertensive activity of celiprolol. Angiology 1999, 50:797-803.
25. Kario K, Shimada K: Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens 1997, 10:261-268.
26. Uzu T, Kimura G: Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999, 100:1635-1638.
27. Cushman WC: The clinical significance of systolic hypertension. Am J Hypertens 1998, 11:182S-185S.
28. Cushman WC, Materson BJ, Williams DW, Reda DJ: Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001, 38:953-957.
29. London GM, Safar ME, Sassard JE, et al.: Renal and systemic hemodynamics in sustained essential hypertension. Hypertension 1984, 6:743-754.
30. Messerli FH, Sundgaard-Riise K, Ventura HO, et al.: Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983, 2:983-986.
31. Folkow B: Physiological aspects of primary hypertension. Physiol Rev 1982, 62:347-504.
32. Lund-Johansen P: Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol. J Cardiovasc Pharmacol 1979, 1:487-495.
33. Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA: Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1988, 1:91-96.
34. Messerli FH, Oren S, Grossman E: Left ventricular hypertrophy and antihypertensive therapy. Drugs 1988, 35:27-33.
35. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507-1513.
36. Schulman SP, Weiss JL, Becker LC, et al.: The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990, 322:1350-1356.
37. Neaton JD, Grimm RH Jr., Prineas RJ, et al.: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993, 270:713-724.
38. Gottdiener JS, Reda DJ, Massie BM, et al.: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997, 95:2007-2014.
39. Mathew J, Sleight P, Lonn E, et al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104:1615-1621.
40. Grossman E, Messerli FH: End-organ disease in hypertension: what have we learned? J Cardiovasc Pharmacol 1992, 20:S1-S6.
41. Schiffrin EL, Park JB, Pu Q: Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002, 20:71-78.
42. Schiffrin EL: Small artery remodeling in hypertension: can it be corrected? Am J Med Sci 2001, 322:7-11.
43. Schiffrin EL, Deng LY, Larochelle P: Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994, 23:83-91.
44. Schiffrin EL, Deng LY, Larochelle P: Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I- converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens 1995, 8:229-236.
45. Baumbach GL, Siems JE, Heistad DD: Effects of local reduction in pressure on distensibility and composition of cerebral arterioles. Circ Res 1991, 68:338-351.
46. Hollenberg NK, Epstein M, Basch RI, Merrill JP: "No man's land" of the renal vasculature. An arteriographic and hemodynamic assessment of the interlobar and arcuate arteries in essential and accelerated hypertension. Am J Med 1969, 47:845-854.
47. Schmieder RE, Schachinger H, Messerli FH: Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension 1994, 23:351-357.
48. Bauer JH, Brooks CS: Volume studies in men with mild to moderate hypertension. Am J Cardiol 1979, 44:1163-1170.
49. Kasiske BL, Kalil RS, Ma JZ, et al.: Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med 1993, 118:129-138.
50. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995, 155:1073-1080.
51. Marcantoni C, Ortalda V, Lupo A, Maschio G: Progression of renal failure in diabetic nephropathy. Nephrol Dial Transplant 1998, 13:16-19.
52. Klein R, Klein BE, Moss SE, et al.: The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 1999, 22:743-751.
53. Bianchi S, Bigazzi R, Campese VM: Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999, 34:973-995.
54. Slataper R, Vicknair N, Sadler R, Bakris GL: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993, 153:973-980.
55. Bakris GL, Mangrum A, Copley JB, et al.: Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997, 29:744-750.
56. Shiigai T, Hattori K, Iwamoto H, Owada A: Long-term enalapril therapy in patients with chronic renal failure on a low-protein diet. A prospective randomized comparison with metoprolol. Nephron 1998, 79:148-153.
57. Weidmann P, Ferrier C, Saxenhofer H, et al.: Serum lipoproteins during treatment with antihypertensive drugs. Drugs 1988, 35:118-134.
58. Grimm RH Jr.: Antihypertensive therapy: taking lipids into consideration. Am Heart J 1991, 122:910-918.
59. Roberts WC: Recent studies on the effects of beta blockers on blood lipid levels. Am Heart J 1989, 117:709-714.
60. Kasiske BL, Ma JZ, Kalil RS, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995, 122:133-141.
61. Skarfors ET, Lithell HO, Selinus I, Aberg H: Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989, 298:1147-1152.
62. Bengtsson C, Blohme G, Lapidus L, et al.: Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12-year prospective population study of women in Gothenburg, Sweden. J Intern Med 1992, 231:583-588.
63. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in a double-blind cross- over study in hypertensive patients. Blood Press 1992, 1:92-101.
64. Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989, 298:1152-1157.
65. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
66. Lakatta EG, Gerstenblith G, Angell CS, et al.: Diminished inotropic response of aged myocardium to catecholamines. Circ Res 1975, 36:262-269.
67. Guarnieri T, Filburn CR, Zitnik G, et al.: Contractile and biochemical correlates of beta-adrenergic stimulation of the aged heart. Am J Physiol 1980, 239:H501-H508.
68. Feldman RD, Limbird LE, Nadeau J, et al.: Alterations in leukocyte beta-receptor affinity with aging. A potential explanation for altered beta-adrenergic sensitivity in the elderly. N Engl J Med 1984, 310:815-819.
69. Stratton JR, Cerqueira MD, Schwartz RS, et al.: Differences in cardiovascular responses to isoproterenol in relation to age and exercise training in healthy men. Circulation 1992, 86:504-512.
70. Vlachakis ND, Aledort L: Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 1980, 45:321-325.
71. Fleg JL, Schulman S, O'Connor F, et al.: Effects of acute beta-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. Circulation 1994, 90:2333-2341.